Evidence map›Paper›PMID 36747082›Full record

ArticleNature cell biology2023

Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis.

Xiaoguang Liu, Litong Nie, Yilei Zhang, Yuelong Yan, Chao Wang, Medina Colic, Kellen Olszewski, Amber Horbath, Xiong Chen, Guang Lei and 9 more

Open access · greenAbstract read
In one paragraph

Article in Nature cell biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 769 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
769citing papers in PubMed, 1 pooled it
284.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

769 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,059 citations in OpenAlex.

  1. Metabolic cell death in cancer: mechanisms and therapeutic potential.Apoptosis : an international journal on programmed cell death · 2025
    Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. The emerging roles of disulfidptosis in cancer.Apoptosis : an international journal on programmed cell death · 2026
    Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Disulfidptosis: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026
    Review
  17. Article
  18. Article
  19. Article
  20. Review

709 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

19 authors at 2 institutions in 1 country.

Xiaoguang Liu *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-6977-5128
Litong Nie *Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-0326-4517
Yilei ZhangDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1407-0301
Yuelong YanDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0001-8495-6445
Chao WangDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Medina ColicDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0003-1442-1589
Kellen OlszewskiKadmon Corporation (A Sanofi Company), LLC, New York, NY, USA.
Amber HorbathDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Xiong ChenDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Guang LeiDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID http://orcid.org/0000-0002-3282-0666
Chao MaoDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Shiqi WuDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Li ZhuangDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Masha V PoyurovskyKadmon Corporation (A Sanofi Company), LLC, New York, NY, USA.
M James YouDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Traver HartDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Daniel D BilladeauDivision of Oncology Research, Schulze Center for Novel Therapeutics, Mayo Clinic College of Medicine, Rochester, MN, USA.
Junjie ChenDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. jchen8@mdanderson.org.ORCID http://orcid.org/0000-0002-1493-2189
Boyi GanDepartment of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. bgan@mdanderson.org.ORCID http://orcid.org/0000-0001-8884-6040
The University of Texas MD Anderson Cancer Center · USMayo Clinic · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Regulation of Nutrient Homeostasis by COMMD proteinsR01DK107733 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI DANIEL D BILLADEAU, Ezra Burstein · 2016 to 2026
$4.6M
High-content microscopy platform for multiplex perturbation/multiplex readout studiesR35GM130119 · NIGMS · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Traver Hart · 2018 to 2026
$3.9M
Studying metabolic stress signaling in renal cancerR01CA181196 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2014 to 2024
$3.4M
Targeting SLC7A11-induced nutrient dependency in cancer: mechanisms and preclinical translationR01CA244144 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2020 to 2024
$2.1M
Targeting ferroptosis in cancer therapyR01CA269646 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Boyi Gan · 2023 to 2026
$2.0M
Targeting ferroptosis in radioresistance in lung cancer: mechanisms and preclinical translationR01CA247992 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GAN, BOYI · 2021 to 2025
$1.9M
NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA181196NCI NIH HHS R01 CA244144NCI NIH HHS R01 CA247992NCI NIH HHS R01 CA269646NIDDK NIH HHS R01 DK107733NIGMS NIH HHS R35 GM130119
6 · The paper itself

Abstract

SLC7A11-mediated cystine uptake suppresses ferroptosis yet promotes cell death under glucose starvation; the nature of the latter cell death remains unknown. Here we show that aberrant accumulation of intracellular disulfides in SLC7A11

Indexed as

DisulfidesNeoplasmsActin CytoskeletonApoptosisGlucoseHumansDisulfidesGlucose

Identifiers

PMID36747082
PMCPMC10027392
OpenAlexW4319310752

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.